Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Warren Kati | ||||||||||||
Title | ABBV-744: A first-in-class highly BDII-selective BET bromodomain inhibitor | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/DDT01-05 | ||||||||||||
Abstract Text | Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-744 | ABBV744|ABBV 744 | BET Inhibitor (Pan) 32 | ABBV-744 is a bromodomain II selective BET inhibitor that demonstrates anti-proliferative activity (Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05, PMID: 31969702, PMID: 32324999). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|